LYEL
Lyell Immunopharma, Inc. NASDAQ Listed Jun 17, 2021$19.91
Mkt Cap $464.6M
52w Low $7.65
32.8% of range
52w High $45.00
50d MA $22.20
200d MA $20.09
P/E (TTM)
-1.3x
EV/EBITDA
-2.6x
P/B
1.4x
Debt/Equity
0.2x
ROE
-110.6%
P/FCF
-3.5x
RSI (14)
—
ATR (14)
—
Beta
-0.07
50d MA
$22.20
200d MA
$20.09
Avg Volume
101.2K
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
201 Haskins Way · South San Francisco, CA 94080 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -2.15 | -7.68 | -257.2% | 24.78 | +0.0% | -14.2% | -14.7% | -18.7% | -19.0% | -16.2% | — |
| Nov 12, 2025 | AMC | -2.81 | -2.13 | +24.2% | 17.63 | -3.6% | -1.2% | -4.0% | -1.2% | +1.7% | -2.3% | — |
| Aug 12, 2025 | AMC | -3.80 | -2.89 | +23.9% | 10.57 | -12.2% | +2.5% | +1.8% | +0.1% | +3.0% | +2.5% | — |
| May 13, 2025 | AMC | -3.80 | -3.60 | +5.3% | 8.09 | -0.7% | -3.6% | -0.7% | +2.6% | +2.1% | +4.3% | — |
| Mar 11, 2025 | AMC | -0.18 | -0.72 | -300.0% | 13.31 | +2.2% | +0.9% | -8.9% | -12.0% | -22.3% | -27.3% | — |
| Nov 7, 2024 | AMC | -0.20 | -0.17 | +15.0% | 24.40 | +3.3% | +0.0% | -0.8% | -4.1% | -9.8% | -9.8% | — |
| Aug 7, 2024 | AMC | -0.20 | -0.18 | +10.0% | 28.20 | -0.7% | +6.4% | +8.5% | -3.5% | -2.8% | -14.9% | — |
| May 6, 2024 | AMC | -0.20 | -0.24 | -20.0% | 50.80 | -3.1% | +0.0% | -1.6% | +5.5% | -3.1% | -5.5% | — |
| Feb 28, 2024 | AMC | -0.21 | -0.20 | +4.8% | 56.80 | -3.5% | +2.8% | +8.1% | -8.1% | -11.6% | -7.0% | — |
| Nov 7, 2023 | AMC | -0.27 | -0.20 | +25.9% | 45.00 | -0.9% | +4.4% | -2.7% | -26.4% | -31.1% | -15.6% | — |
| Aug 8, 2023 | AMC | -0.30 | -0.26 | +13.3% | 48.00 | +0.0% | -0.4% | -3.8% | -3.8% | -8.3% | -4.6% | — |
| May 4, 2023 | AMC | -0.28 | -0.27 | +3.6% | 48.40 | +5.0% | +2.5% | -5.0% | +2.1% | +7.9% | +4.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | Baird | Initiates | Outperform | $49 | $19.73 | $20.03 | +1.5% | +5.6% | +5.0% | +4.5% | +5.7% | +1.7% |
| Dec 9 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $28.36 | $29.00 | +2.3% | +3.2% | +10.3% | +17.8% | +21.5% | +14.2% |
| Nov 24 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $19.13 | $19.27 | +0.7% | +18.8% | +17.8% | +27.6% | +25.5% | +15.5% |
| Jun 24 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.99 | $9.29 | +3.3% | +6.7% | +3.3% | +1.4% | -0.6% | -1.7% |
| Apr 16 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $9.18 | $8.79 | -4.2% | -4.4% | -5.6% | -4.7% | +0.2% | +4.1% |
| Mar 13 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $13.43 | $13.52 | +0.7% | -9.7% | -12.8% | -23.0% | -28.0% | -13.3% |
| Nov 12 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $24.20 | $23.60 | -2.5% | -3.3% | -9.1% | -9.1% | -9.1% | -8.3% |
| Oct 30 | BofA Securities | Downgrade | Buy → Underperform | — | $18.96 | $18.56 | -2.1% | -9.4% | +1.3% | +18.1% | +34.0% | +30.8% |
| Oct 28 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $18.54 | $17.60 | -5.1% | +1.0% | +2.3% | -7.4% | +3.6% | +20.8% |
| Aug 19 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $24.40 | $24.20 | -0.8% | +19.7% | +18.9% | +19.7% | +18.9% | +27.9% |
| Jun 27 | BofA Securities | Maintains | Buy → Buy | — | $26.20 | $26.20 | +0.0% | +5.3% | +10.7% | +20.6% | +15.3% | +15.3% |
| Jun 27 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $26.20 | $26.20 | +0.0% | +5.3% | +10.7% | +20.6% | +15.3% | +15.3% |
| May 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.80 | $49.20 | -3.1% | +0.0% | -1.6% | +5.5% | -3.1% | -5.5% |
| Feb 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $56.80 | $54.80 | -3.5% | +2.8% | +8.1% | -8.1% | -11.6% | -7.0% |
| Nov 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $47.00 | $47.00 | +0.0% | -6.8% | -29.6% | -34.0% | -19.1% | -12.8% |
| Aug 28 | JP Morgan | Downgrade | Overweight → Neutral | — | $45.80 | $44.00 | -3.9% | -3.9% | +0.9% | +2.6% | +4.4% | +2.2% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.00 | $47.40 | -1.2% | -6.2% | -7.5% | -12.1% | -12.9% | -14.2% |
| Jan 24 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $59.60 | $58.80 | -1.3% | +2.0% | +7.0% | +10.1% | +12.1% | +9.7% |
| Nov 14 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $90.60 | $89.60 | -1.1% | +3.8% | +1.5% | -1.8% | -2.6% | -3.1% |
| Nov 11 | Goldman Sachs | Downgrade | Buy → Neutral | — | $99.20 | $95.80 | -3.4% | -8.7% | -5.2% | -7.3% | -10.3% | -11.1% |
| May 24 | Goldman Sachs | Maintains | Buy → Buy | — | $85.60 | $84.40 | -1.4% | -1.9% | -4.0% | -4.4% | +1.4% | -3.3% |
| Mar 31 | Goldman Sachs | Maintains | Buy → Buy | — | $107.20 | $107.80 | +0.6% | -5.8% | +0.0% | +0.0% | -1.3% | -3.0% |
| Jan 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $131.60 | $130.40 | -0.9% | -2.0% | -3.0% | +0.6% | +2.4% | -4.6% |
No insider trades available.
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
LYEL's new executive Lang receives competitive compensation ($560K base plus 40% bonus potential) with full 2026 bonus eligibility, signaling board confidence in his leadership and commitment to retention during critical strategic execution.
Apr 15
8-K
Unknown — 8-K Filing
Lyell's Phase 3 trial of ronde-cel versus competitor CAR-T therapies represents a pivotal commercialization milestone that could validate differentiation and significantly expand addressable market if successful.
Mar 12
8-K
Lyell Immunopharma, Inc. -- 8-K Filing
Lyell Immunopharma appointed a new executive officer with participation in the company's severance plan, potentially affecting shareholder equity structure and executive compensation costs.
Mar 9
Data updated apr 25, 2026 8:16pm
· Source: massive.com